Clinical Trial Update: Safety and Dose Finding Study of Xigris in Hemodialysis Patients [Phase 2]

View source ↗

Summary

Phase 2 safety and dose-finding trial of Xigris in patients with end-stage renal disease has been completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Xigris (Drotrecogin alfa (activated))

Snippet

Sponsor: George Washington University | Conditions: End Stage Renal Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-02-03